Home Tags CDMO

Tag: CDMO

Courtesy: Fotolia

The Evolving Market for Antibody-drug Conjugates

The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat...

Rapidly Expanding MabPlex International Secures U.S. $ 59.1 Million Series A...

In an announcement made to the international business and financial press, MabPlex International, a global Contract Development and Manufacturing Organization or CDMO based in...

Evolution of Antibody-Drug Manufacturing

Antibody-drug Conjugates (ADCs) have evolved since the initial approval of gemtuzumab ozogamicin (Mylotarg®) in 2000, with respect to conjugation, linker and toxin chemistries and...

Poor Aggregation: Failing ADC Targets, Long Delays in Development and Wasted...

During all stages of development, including expression, refolding, downstream processing, formulation, sterilization, and storage, biotherapeutic proteins are subjected to aggregation and degradation.  In the...

ADC Biotechnology Invests in New Bioconjugation Facility in North Wales, United...

UK-based ADC Biotechnology has secured investment for the construction of an $11 million* bioconjugation facility at its new site in Deeside, North Wales, UK. The...
MabPlex Building

Andrew Huang: “ADC’s Are Among the most Powerful Options to...

With a population of 1.4 billion and a rapidly expanding economy, China has become a manufacturing powerhouse. In addition, China is pursuing a...

EAG Laboratories: Unifying Brands to Leverage Global Contract Research and Testing...

Earlier this week, Evans Analytical Group®, better known as EAG, a global scientific services company offering testing, analysis and characterization to technology- and life-science-related...

Goodwin Biotechnology: Mastering Novel Conjugation Approaches

Often described as target-seeking molecular missiles with a lethal warhead, antibody-drug conjugates have, over the last 15 years, shown to have staying power. With...

Q&A – an Interview with Lonza’s Laurent Ducry

Antibody-drug Conjugates or ADCs are among the most exciting drug developments of the last decade. The combination of potent, small molecule drugs with the...

Althea Expands Simplified Manufacturing Supply Chain Service for ADC Development

Biopharmaceutical contract development and manufacturing organization (CDMO) Ajinomoto Althea earlier today announced that it is expanding its existing biological drug product manufacturing operations to include highly...